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Objectives This study sought to examine the efﬁcacy and safety of 3 novel devices to recanalize
coronary chronic total occlusions (CTOs).
Background Successful percutaneous coronary intervention (PCI) of CTOs improves clinical outcome
in appropriately selected patients. CTO PCI success, however, remains suboptimal.
Methods A new crossing catheter and re-entry system was evaluated in a prospective, multicenter,
single-arm trial of CTO lesions refractory to standard PCI techniques. The primary efﬁcacy endpoint
was the frequency of true lumen guidewire placement distal to the CTO (technical success).
Results Enrollment included 147 patients with 150 CTOs. The mean lesion length was 41  17 mm.
A crossing catheter crossed 56 lesions into the distal true lumen, and a re-entry catheter facilitated
tapered-wire cannulation of the distal lumen in 59 CTOs initially crossed subintimally (77% technical
success). Success in the ﬁrst 75 CTOs was 67%, rising to 87% in the last 75 CTOs. Mean ﬂuoroscopy
and procedure times were 45  16 min and 90  12 min, respectively, each signiﬁcantly shorter
than in historical controls (p  0.0001 for both). Coronary perforation occurred in 14 cases (9.3%),
requiring treatment in 3 cases (prolonged balloon inﬂation, with additional coil embolization in 1
case). No tamponade or hemodynamic instability occurred. Six patients had periprocedural non–ST-
segment elevation myocardial infarction. No emergency surgery, ST-segment elevation myocardial
infarction, or cardiac reintervention occurred. Two deaths occurred within 30 days, neither as a di-
rect result of the procedure. The 30-day major adverse cardiac event rate was 4.8%.
Conclusions In CTOs failing standard techniques, use of a new crossing and re-entry system results in a
high success rate without increasing complications. (J Am Coll Cardiol Intv 2012;5:393–401) © 2012 by
the American College of Cardiology Foundation
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394Coronary chronic total occlusions (CTOs) remain the most
challenging lesion subset in percutaneous coronary interven-
tion (PCI). Although there are isolated reports of success
rates approaching 90% (1,2), most multicenter studies still
report success in the 70% range (3–5) even with utilization
of modern tools and retrograde collateral approaches. Fail-
ure to cross with a wire remains the most common mode of
CTO PCI failure (6).
Because of slow adoption of retrograde collateral tech-
niques and the conservative approach to CTO PCI in the
United States (7) in addition to the suboptimal crossing
rate, the CrossBoss catheter and Stingray re-entry system
(BridgePoint Medical System, BridgePoint Medical, Plym-
outh, Minnesota) were developed to simplify and potentially
improve antegrade recanalization success (8–10). We per-
formed the FAST-CTOs (Facilitated Antegrade Steering
Technique in Chronic Total Occlusions) trial to evaluate
the BridgePoint Medical System in refractory coronary
CTOs.
Methods
Study design. The FAST-
CTOs trial (Clinical Trials ID:
NCT00886899) was a prospective,
multicenter, single-arm clinical
trial designed to test the hypoth-
esis that use of BridgePoint de-
vices in coronary CTO lesions
refractory to PCI using standard
techniques is associated with su-
perior efficacy and similar com-
plications compared with histor-
ical controls.
The study was performed at 16 clinical sites (Online
ppendix). The Food and Drug Administration approved
he study protocol, and institutional review boards at all sites
pproved the consent form. Patients were followed for 30
ays post-procedure for assessment of adverse events. An
ndependent data and safety monitoring committee re-
iewed and adjudicated all adverse events.
Patients. Patients with total occlusion (Thrombolysis In
Myocardial Infarction flow grade 0) of a major epicardial
coronary vessel clinically determined to be 3 months old
were considered for this study. Patients had to report angina
or have ischemia documented on a stress test and have an
angiographic landing zone 10 mm proximal to any major
bifurcation without severe calcification. Lesion length was
not considered in study eligibility.
One of 3 methods of failure to cross the CTO with
standard techniques was needed to demonstrate refractori-
ness: a failed attempt to cross the CTO within the previous
Abbreviations
and Acronyms
CTO  chronic total
occlusion
MACE  major adverse
cardiac event(s)
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STAR  subintimal tracking
and re-entryyear; a failed concurrent attempt with 10 to 15 min offluoroscopy time; or subintimal wire position during the
concurrent attempt.
Exclusions included left ventricular ejection fraction
20%, vein graft or in-stent CTO target lesion, allergy to
aspirin or all thienopyridines, aorto-ostial lesion location,
creatinine 2.3 mg/dl, or PCI within the previous 2 weeks.
If the patient met all inclusion and no exclusion criteria
before entering the catheterization laboratory, the patient could
consent to enter the study. If there had been no prior failed
attempt, the patient understood he/she would not be included
in the trial unless standard techniques failed to cross the lesion.
The BridgePoint Medical System. Once 1 of the 3 refractory
riteria was met, the BridgePoint System could be used. The
ystem consists of 3 parts. The first is an over-the-wire
atheter (Fig. 1) with a 1-mm blunt tip rotated rapidly by
he operator to dissipate friction to facilitate CTO crossing.
ny standard 0.014-inch guidewire can be used to deliver
his catheter to the CTO. The wire is then retracted and the
atheter advanced. If the crossing catheter traverses the
TO into the distal true lumen, a long PCI guidewire can
e placed, and the catheter can be removed. Standard
alloon angioplasty and stenting techniques are then used.
If the crossing catheter enters the subintimal space, it is
dvanced next to the angiographically visible true lumen
istal to the CTO (re-entry site). An exchange wire is left in
lace, and the second component of the BridgePoint Sys-
em, the re-entry balloon catheter (Fig. 2), is advanced over
he guidewire to the re-entry site. This 2.5  10-mm flat
alloon is designed to be inflated in the subintimal space to
to 4 atm. The inflated balloon provides leverage for a
edicated re-entry guidewire to engage 1 of 2 exit ports
ffset by 180°, 1 of which will always point toward the true
umen by design. The exchange guidewire is then removed.
oronary angiography is performed in multiple views to
elineate the position of the re-entry balloon relative to the
rue lumen.
Figure 1. Crossing Catheter
The CrossBoss catheter (BridgePoint Medical System, BridgePoint Medical)
is an over-the-wire device (0.014-inch guidewire compatible) with a 1-mm
rounded tip, a coiled shaft, and a moveable proximal torque device that
releases under high torque to prevent product damage.
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395The third part of the System consists of a 12-gram
tapered-tip, angulated guidewire designed for re-entry
through 1 of the exit ports (Fig. 2). The re-entry wire is
advanced through the exit oriented toward the true lumen.
If the incorrect exit port is engaged, this is seen fluoroscop-
ically, and the guidewire is rotated 180° to engage the
correct port. The wire is directed to puncture and re-enter
the distal true lumen. If the re-entry guidewire cannot be
advanced in the distal vessel, it is exchanged for a softer wire
that is used through the same exit port utilizing the puncture
tract created by the re-entry guidewire to track the distal vessel.
If intraluminal position is not achieved, the balloon is deflated
and moved to attempt re-entry from another arterial segment.
After re-entry, the catheter is deflated and removed. An
over-the-wire balloon catheter is then inserted and the re-entry
wire can be exchanged for a workhorse wire. Balloon angio-
plasty and stenting are used to recanalize the CTO.
CTO procedure and clinical follow-up. The CTO PCI pro-
edures were performed at each cardiac catheterization
aboratory per the institution’s standard protocol. Heparin
as used as the anticoagulant. Drug-eluting stents were
sed preferentially for stenting the occlusion. Use of aspirin
nd a thienopyridine was at the discretion of the operators.
hree serial blood draws were taken to measure creatinine
inase (CK) and CK-myocardial band (CK-MB) every 6 to
h post-procedure for 24 h or through discharge. To be
onsistent with historical control studies, a non–ST-
egment elevation myocardial infarction (NSTEMI) was
iagnosed if any total CK measurement was 2 times
ormal and the CK-MB level was elevated. Patients re-
urned for an office visit 30 days post-procedure to be
Figure 2. Re-Entry Balloon Catheter and Guidewire
The Stingray Orienting Balloon Catheter (BridgePoint Medical System,
BridgePoint Medical) is an over-the-wire, 10-mm-long, 2.5-mm-wide, ﬂat
balloon catheter designed to deploy within the subintimal plane, with exit
ports on either side of the balloon. Marker bands identify the location of
the exit ports. The Stingray guidewire has a 28° bend and a distal probe
that extends from the tip to aid re-entry.ssessed for adverse events. rEndpoints. The primary efficacy endpoint of the trial was
echnical success defined as the ability of the BridgePoint
ystem to successfully facilitate placement of a guidewire
eyond the CTO into the distal true lumen. The primary
afety endpoint was major adverse coronary events (MACE)
cardiac death, myocardial infarction, target lesion revascu-
arization, or emergency bypass surgery) through 30 days
ost-procedure. Secondary endpoints included total proce-
ure time, total fluoroscopy time, and procedural success
opening of the CTO with50% residual stenosis and final
hrombolysis In Myocardial Infarction antegrade flow
rade 2 to 3 in the absence of Q-wave myocardial infarction,
mergency repeat revascularization, or in-hospital death).
Quantitative coronary angiography. Two angiographic core
laboratories were used for this study. The Cardiovascular
Research Foundation (Columbia University, Ecaterina
Cristea, MD, Director) reviewed cases to verify subintimal
guidewire position in cases where this was the criterion used
as the failure mode for study entry. The Yale Cardiovascular
Research Group (Yale University, Alexandra Lansky, MD,
Director) performed qualitative analysis and quantitative
coronary angiography.
Statistical analysis. Continuous variables were summarized
s mean  1 SD or as median (range), and discrete variables
were presented as frequencies. Descriptive statistics are reported.
Comparison of the event rates observed in the FAST-CTOs trial
with historical data from prior published studies was performed
using the most appropriate 1-sample exact test for categorical
values and the Wilcoxon rank sum or Student t test for continuous
variables. A p value of 0.05 was considered significant.
Power calculation and comparisons with historical controls.
Using literature with similar methods and definitions of
MACE to FAST-CTOs, the MACE rate of historical
controls was estimated to be 7% (11–17). To demonstrate
the BridgePoint System had a 30-day MACE rate that was
not significantly higher than this (14%), a sample size of 141
patients was required (  0.05,   0.20 testing for
oninferiority). To account for potential dropout during
ollow-up, a sample size of 149 was chosen.
Published literature of CTO crossing using various
uidewires and devices (comparable to the primary efficacy
ndpoint “technical success” in the present study) showed a
ean crossing rate of 59% (12,13,15–24). Procedure and
uoroscopy times in historical controls were 146 and 53
in, respectively (22–26).
esults
Patients. Between March 2009 and July 2010, 147 patients
with 150 coronary CTOs (3 patients had 2 CTOs) were
enrolled. The crossing catheter was the only investigational
device used for 73 CTOs (n 70). A case example is shown
in Figure 3. Seven CTOs (n  7) were treated with the
e-entry catheter and guidewire as the only investigational
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396devices, and 70 CTOs (n  70) were treated with all 3 new
devices. A representative crossing and re-entry case is shown
in Figure 4.
We defined failed attempts to cross the CTO as an
attempt within the past year (61 CTOs, 41%), concurrent
A
C
E
Figure 3. Crossing Catheter Case
Previously failed chronic total occlusion of a right coronary artery (arrows, A)
(arrows, B and C) crossing to the distal true lumen (arrowheads, C), facilitatifailure within 10 to 15 min of fluoroscopy time (51 CTOs,34%), or guidewire entry into the subintimal space (38
CTOs, 25%). Subintimal position of the guidewire was
confirmed by the angiographic core laboratory in all 38
cases.
The clinical characteristics of the patients enrolled in the
rossBoss catheter tip (BridgePoint Medical System, BridgePoint Medical)
tal wire placement (arrows, D), pre-dilation, and ﬁnal result (E).B
D
with C
ng distrial are listed in Table 1. Of the 150 CTOs treated, 145
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Figure 4. Re-Entry Case
Chronic total occlusion of a right coronary artery (arrows, A) with CrossBoss catheter tip (BridgePoint Medical System, BridgePoint Medical) (arrows, B and C)
crossing via false lumen (true lumen, arrowheads, E) followed by Stingray catheter placement (BridgePoint Medical System, BridgePoint Medical) (arrow, D),
Stingray guidewire re-entry (arrow, E) through the Stingray catheter into the distal true lumen (arrows, F), pre-dilation, and ﬁnal result (G).
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398had images available for quantitative coronary angiography
analysis by the core laboratory, shown in Table 2.
Success rates. Technical success was achieved in 115 of 150
CTOs attempted (77%). The observed technical success rate
was significantly better than the historical control rate of
59%, p  0.001. Technical success was seen in 72% of cases
with a previously failed prior procedure, 73% of cases with
a failed concurrent attempt, and 89% of cases with subin-
timal guidewire position. Factors associated with higher risk
for failure included smaller vessel size, severe calcification,
severe tortuosity, and side-branch involvement (Table 3).
Stents were implanted in 112 of 115 successfully crossed
CTOs. The mean stented length was 61  24 mm. Stents
could not be successfully positioned in 3 cases with technical
success.
Secondary endpoints. The mean procedure time was 105
4 min, and the fluoroscopy time was 44  25 min, both
ignificantly less than the historical control times of 146 and
3 min, respectively (p  0.0001 for both). Procedure and
uoroscopy times by refractory status of patients were not
ifferent. Procedure time for crossing catheter–only cases
93  50 min) was significantly shorter than for cases
nvolving the re-entry system (115 57 min, p 0.01), but
uoroscopy time was not different (41 25 min vs. 47 25
in, respectively, p  0.09). Procedural success was docu-
ented in 113 of 150 (75%) of the CTOs attempted,
ncluding 1 technical failure with subsequent retrograde
uccess and 1 technical success case that could not be
uccessfully stented and was a procedural failure.
30-day adverse events. The 30-day MACE rate was 4.8%.
Two patients died. The first death occurred in a patient
admitted 22 days after a successful procedure with leg pain
due to an embolic occlusion of the superficial femoral artery,
secondary to atrial fibrillation. The patient expired of respira-
tory arrest in the hospital 3 days later. The second patient died
16 days after an unsuccessful attempt to recanalize his CTO,
during which he experienced an NSTEMI. He was discharged
and presented to the emergency department of his local
Table 1. Clinical Characteristics of the Study Patients (N  147)
Age, yrs 63.3 9.1
Men 127 (86)
Diabetes mellitus 53 (36)
Hyperlipidemia 88 (62)
Hypertension 75 (52)
Family history of coronary artery disease 52 (37)
Tobacco use 28 (19)
Prior myocardial infarction 58 (39)
Angina pectoris 126 (86)
Prior coronary artery bypass graft surgery 33 (22)
Prior attempt to recanalize a chronic total occlusion 67 (46)
Values are mean SD or n (%).hospital with asystole and could not be resuscitated.Four patients had asymptomatic NSTEMI following
successful recanalization of their CTO. One patient without
technical success had successful recanalization with a retro-
grade approach but also had an asymptomatic NSTEMI.
The sixth patient with an NSTEMI was discussed in the
previous text. No patient had an ST-segment elevation myo-
cardial infarction, emergency bypass surgery, or target vessel
revascularization. One patient experienced a left thalamic
infarct with symptom resolution before 30-day follow-up.
The observed MACE rate of 4.8% was sufficiently low
enough to reject the null hypothesis that the BridgePoint
system has a MACE rate higher than historical controls
with a p value of 0.0003. The observed 30-day MACE was
not significantly different from the expected historical con-
trol MACE rate of 6.9% (p  0.40).
Fourteen perforations (9.3%) were noted during the
study. Four occurred when the crossing catheter entered a
small branch, causing dye extravasation (3 Ellis grade I and
1 grade III). Two of these patients were treated with
protamine administration and prolonged balloon inflation
and had technical failure. Two were technically successful,
and the perforations were not treated. A fifth patient had a
re-entry catheter balloon burst in the artery, causing a type
II perforation requiring no treatment. Nine patients had
perforation noted after use of a nonstudy device (8 guide-
wires, 1 balloon catheter). Eight of these cases (grade I)
required no treatment, and 1 (grade II) was treated with
prolonged balloon inflation followed by coil embolization.
There was no occurrence of tamponade, pericardiocentesis,
or emergency surgery.
Discussion
The FAST-CTOs trial demonstrates that use of the
BridgePoint Medical System in coronary CTOs refractory
Table 2. Quantitative Coronary Angiographic Core Laboratory Data
Measure n Pre-Procedure Post-Procedure
Proximal RVD, mm 145 3.12 0.53 3.20 0.51
MLD, mm 145 0.00 0.00 1.75 1.06
% diameter stenosis 145 100 0.00 35 37
Stented length, mm 110 — 61.3 23.9
Blunt proximal cap 145 64 (45) —
Funnel-shaped proximal cap 145 81 (56) —
Occlusion length, mm
Mean  SD 143 22 13 —
Median (range) 20 (3–97) —
Lesion length, mm
Mean  SD 140 41 17 —
Median (range) 40 (11–89) —
Side-branch involvement 145 97 (67) —
Values are mean SD or median (range).MLDminimal lumen diameter; RVD reference vessel diameter.
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399to crossing with standard techniques was associated with
higher technical success (77% vs. 59%, p  0.001), shorter
fluoroscopy and procedural times (p 0.0001 for both), and
similar 30-day MACE (4.8% vs. 6.9%, p  0.40) compared
with historical controls.
The BridgePoint System was designed to either primarily
cross into the distal true lumen or to re-enter the true lumen
from the subintimal space distal to the CTO. These new
devices offer a systematic approach to CTO PCI. The
over-the-wire crossing catheter can be successful in
crossing into the distal true lumen and was the only step
needed for technical success in 56 of 150 CTOs (37%).
Advancement into the subintima, a common mode of
failure in CTO PCI, can be addressed with a second step
involving the use of a dedicated coronary re-entry balloon
designed to provide support for guidewire penetration
into the adjacent true lumen. A stiff guidewire with a
short curve and distal probe was highly successful in
obtaining distal true lumen positioning with technical
success in 59 of 77 attempted cases (77%). Previous
smaller series have been reported utilizing this coronary
re-entry system (8 –10), but this is the largest study
detailing clinical results with coronary re-entry.
The technical success rate of 77% is higher than that of
previous device studies (13,17,26). Increased familiarity
with the device was associated with higher success rates
(67% for the first 75 CTOs, improving to 87% in the last 75
CTOs), suggesting that familiarity with the different com-
ponents of the BridgePoint System improves the likelihood
Table 3. Technical Success by Treated Artery and Op
Characteristic by CTO
Inciden
(n  15
Right coronary artery 71% (106
Left anterior descending artery 19% (29)
Left circumﬂex artery 10% (15)
Ipsilateral collaterals 23% (34)
Contralateral collaterals 47% (70)
Both ipsilateral and contralateral collaterals 31% (46)
Bridging collaterals 37% (56)
Baseline RVD
Mean  SD 2.9 0
Median (range) 3 (2.0–
CTO length
Mean  SD 32.3 2
Median (range) 25 (3–1
Moderate or severe calciﬁcation 35% (52)
Moderate or severe tortuosity 43% (64)
45° angulation 28% (42)
Moderate or severe side-branch involvement 35% (53)
Values are % (n), mean SD, or median (range). *Freeman-Halton ex
CTO chronic total occlusion; RVD reference vessel diameter.of successful CTO crossing. SOver 40% of the patients entered into the current trial
had previously failed procedures. In the present study, the
success rate for this specific subgroup of patients was 72%.
This compares favorably to the recently reported Japanese
CTO registry where these previously failed cases were
primarily treated with a retrograde approach by expert CTO
operators, and procedural success was also 72% (4).
PCI of CTOs with the present system is quite different
from the subintimal tracking and re-entry (STAR) tech-
nique described by Colombo et al. (27). With STAR, the
operator tries to gain subintimal wire position as soon as
possible, and extends a dissection to the distal artery where
all significant-sized individual side branches are sequentially
attempted to be reconnected to the true lumen, With the
BridgePoint devices, over one-third of cases can be traversed
via the true lumen with the crossing catheter without
dissection. If the crossing catheter becomes subintimal, then
this catheter is advanced only to the angiographic true
lumen re-entry point where the re-entry device is employed
to regain the true lumen without extending the dissection
any further than necessary. Re-entry is attempted in a major
epicardial vessel rather than into individual branch vessels.
STAR is generally considered a method of last resort to
open a CTO, where the BridgePoint system in the present
study was used as a frontline device after conventional wire
failure.
Stented length was quite long in both the present study
(61  23 mm) and in the initial report of the STAR
echnique (42  24 mm), but possibly for different reasons.
r-Assessed Lesion Characteristics
Technical Success
(n  115)
Technical Failure
(n  35) p Value
77% (82) 23% (24)
76% (22) 24% (7) 0.91*
73% (11) 27% (4)
68% (23) 32% (11) 0.21*
76% (53) 24% (17)
85% (39) 15% (7)
82% (46) 18% (10) 0.24†
3.0 0.4 2.8 0.4 0.03‡
3 (2.0–3.6) 3 (2.0–3.5)
31.0 20.0 36.5 23.0 0.29‡
25 (3–105) 30 (10–100)
63% (33) 37% (19) 0.01*
67% (43) 33% (21) 0.02†
76% (32) 24% (10) 1.00†
66% (35) 34% (18) 0.03†
; †Fisher exact test; ‡Wilcoxon test.erato
ce
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400design, whereas in the present study, lesion length with
50% stenosis measured by the core laboratory before
intervention was 41  17 mm. To stent from normal
segment to normal segment required a dramatic stent length
in both these studies. Long-term follow-up will clearly be
necessary to determine safety and durability with these
techniques that require 40 mm of stent length. However,
30-day data from the present study are encouraging that
acute and subacute thrombosis are at least not overwhelm-
ing issues, but the potential for delayed thrombosis has not
yet been addressed.
Performing CTO PCI with low complication rates is
essential because patients with symptomatic CTO generally
have chronic stable angina with a good prognosis when
treated medically (28). The MACE rate in the current study
was acceptably low, and comparable to the rates previously
found in CTO device studies. The absence of tamponade in
this trial was particularly notable since most cases involved
extraluminal tracking of devices.
Perforations remain a concern with CTO PCI. In the
current study, perforations were documented in 14 cases,
but most (11 of 14). required no treatment or only discon-
tinuation of anticoagulation. No hemodynamic instability
was encountered, and most of the perforations were caused
by noninvestigational devices. Though perforation rates
remain approximately 10% in this and recent CTO PCI
series (4,5), most perforations are grade I (7 of 14) or II (6
of 14 in this series) and are rarely associated with MACE (0
in this study). In the global experience with the crossing
catheter used in this and previous studies (8,9), perforations
in a major epicardial vessel have not been seen, but infre-
quent perforations have been reported when this catheter is
tracked into a small side branch. Therefore, operators
should closely monitor the angiographic course of the
crossing catheter to avoid side branch tracking and possible
perforation.
Because of clinical benefit gained by patients with suc-
cessful CTO PCI (angina relief, quality of life improvement
[29], left ventricular function improvement [30,31], de-
creased need for coronary arterial bypass grafting [32], and
perhaps an improvement in survival [5,33,34]), interest in
CTO PCI has increased globally. However, for many
reasons, CTO PCI remains relatively infrequent in the
United States (7,35). Previous CTO crossing devices that
do not include a re-entry platform (12–17,19) have not had
a major impact on CTO PCI. However, a simplified
stepwise antegrade approach with both crossing and re-
entry capabilities leading to improved success with shorter
procedure times may enable operators to take on more
complex but clinically indicated cases, particularly in the
United States, where success rates and procedure times are
carefully scrutinized.
Study limitations. It was a single-arm study that did not
nclude a concurrent comparator. The sequence and modef use of each device was left to the discretion of each
perator, but this more closely reflects how the device is
ikely to be used in everyday clinical practice. Most of the
TO lesions were located in the right coronary artery;
owever, technical success rates were similar for all 3
oronary artery CTOs.
onclusions
The results of this study suggest that the BridgePoint
System provides antegrade success higher than previous
devices in refractory CTOs, with procedure and fluoroscopy
times significantly shorter than previous CTO studies with-
out increasing MACE.
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For a list of the clinical sites and principal investigators, please see the
online version of this article.
